Core Viewpoint - The article discusses the phenomenon of heavily shorted stocks, highlighting the reasons traders engage in short selling and the potential for short squeezes to create significant price movements in the market [2][3][4]. Group 1: Reasons for Heavy Shorting - Stocks become heavily shorted when experienced traders and institutional investors believe the company is fundamentally overvalued, anticipating a decline in its price [2]. - High short interest indicates a strong conviction among professional traders that the company faces serious risks [2]. Group 2: Short Squeeze Dynamics - Bullish traders, often retail investors, see high short interest as an opportunity for rapid gains through a short squeeze, which occurs when rising stock prices force short sellers to buy back shares, creating a feedback loop that drives prices even higher [3][4]. - The volatility associated with short squeezes can lead to returns that significantly exceed typical stock movements in a short time frame [4]. Group 3: Most Shorted Stocks - As of January 16, 2026, the top 10 most shorted stocks include: - Choice Hotels International, Inc. (CHH) with a short interest of 56.33% - Lucid Group, Inc. (LCID) at 54.45% - Avis Budget Group, Inc. (CAR) at 52.38% - Other notable companies include PureCycle Technologies, Inc. (PCT), Under Armour, Inc. (UAA), and Revolve Group, Inc. (RVLV) with short interests ranging from 39.22% to 41.89% [5][6][7].

Core Insights - ImmunityBio, Inc. has provided an update on the enrollment status of its randomized registrational trial for BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005, indicating that enrollment has exceeded internal expectations and is over 85% complete [1] Enrollment Status - The trial's enrollment is anticipated to reach full capacity by Q2 2026, based on the current enrollment trajectory [1] - The company expects to submit a biologics license application following the completion of the trial [1]

Core Insights - ImmunityBio, Inc. announced updated efficacy and safety results from the QUILT-106 clinical study, evaluating an off-the-shelf allogeneic CD19 CAR-NK therapy combined with rituximab for patients with Waldenström Non-Hodgkin lymphoma, showing promising results in disease control and remission duration [1][2][5] Efficacy and Safety Results - The updated follow-up indicates sustained complete responses lasting up to 15 months, with 100% disease control observed to date [2][3] - Four patients have been enrolled in the study, all maintaining clinical disease control, with two patients showing durable complete remission at 7 and 15 months, respectively [3][4] - The therapy demonstrated rapid onset of complete remission after only two cycles, highlighting the potential for long-term immune-mediated disease control without continuous therapy [4][5] Treatment Protocol - Patients received a total of eight doses of cell therapy in an outpatient setting without lymphodepletion, targeting tumors with both CD19 and CD20 immunotherapies [2][7] - The regimen involved infusing CD19 CAR NK cells with rituximab, administered as two doses per cycle every 21 days for a total of four cycles [2][7] Unique Treatment Approach - This represents the first chemotherapy-free and lymphodepletion-free immunotherapy regimen combining off-the-shelf allogeneic CD19 CAR-NK cells with rituximab, achieving 100% disease control in Waldenström Non-Hodgkin lymphoma [7][8] - The outpatient administration eliminates the need for cytotoxic conditioning and inpatient hospitalization, addressing limitations associated with conventional CAR-T therapies [7][8] Future Directions - Enrollment and follow-up in QUILT-106 are ongoing, with additional clinical updates expected as more patients become evaluable [9] - A follow-up study is being designed to test the combination of NK-CAR with ANKTIVA and rituximab to build on the success of QUILT-106 in treating indolent lymphoma [10]

Core Insights - The shares have experienced a continuous increase on every trading day in 2026, indicating a strong upward trend in the stock performance [1] Company Performance - The consistent rise in share prices suggests positive market sentiment and potential investor confidence in the company's future prospects [1]

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Core Insights - ImmunityBio's Anktiva has shown explosive sales growth, with a projected revenue increase from $15 million in 2024 to $113 million in 2025, representing a 700% growth year-over-year [2][5] - The stock price of ImmunityBio surged by 30.80% to close at $3.95, driven by strong preliminary earnings results and ongoing demand trends for Anktiva [2][5] - Recent approvals and positive clinical data for Anktiva in new indications, such as non-small cell lung cancer, indicate significant geographic expansion potential for the company [6] Company Performance - ImmunityBio's market capitalization stands at $3.0 billion, with a gross margin of 80.41% [2] - The trading volume reached 70.4 million shares, significantly above the three-month average of 13 million shares, indicating heightened investor interest [3] - The stock has experienced a dramatic decline of 89% since its IPO in 2015, highlighting its volatile history [3] Market Context - The S&P 500 and Nasdaq Composite saw minor gains of 0.27% and 0.25% respectively, while ImmunityBio outperformed its biotechnology peers, such as Incyte and Vertex Pharmaceuticals, which experienced declines [4]

Core Insights - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1 - The newsletter is led by a biotech consultant with over 5 years of experience covering the industry and has compiled detailed reports on more than 1,000 companies [1] - The investing group, Haggerston BioHealth, caters to both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, and forecasts for major pharmaceutical companies [1] - The group offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis to aid investors in making informed decisions [1]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Core Viewpoint - ImmunityBio, Inc. is experiencing significant sales momentum, highlighted by a remarkable increase in preliminary net product revenue for its immunotherapy product Anktiva, which is FDA-approved for non-muscle invasive bladder cancer [1][2]. Financial Performance - Preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a 700% year-over-year increase [2]. - For Q4 2025, the company reported revenue of about $38.3 million, surpassing the previous quarter's $31.8 million, marking a 20% quarter-over-quarter increase and a 431% year-over-year increase [3]. - The company noted a 750% increase in unit sales volume for Anktiva in 2025 compared to 2024 [3]. Management Commentary - Richard Adcock, President and CEO, stated that the company delivered strong quarter-over-quarter revenue growth, indicating accelerating adoption of Anktiva and effective execution of its commercial strategy [4]. Cash Position - The company ended the quarter with an estimated $242.8 million in cash, cash equivalents, and marketable securities [4]. Clinical Data - Anktiva demonstrated statistically significant immune restoration in a study involving 151 patients with non-small cell lung cancer, showing a consistent association between lymphocyte recovery and improved survival [5]. Stock Performance - ImmunityBio is currently trading 67.1% above its 20-day simple moving average (SMA) and 58.7% above its 100-day SMA, indicating strong short-term momentum [6]. - The stock has increased 55.44% over the past 12 months and is closer to its 52-week highs than lows [6]. Technical Indicators - The RSI is at 77.54, indicating the stock is in overbought territory, while the MACD is above its signal line, reinforcing bullish sentiment [7]. Analyst Consensus - The stock carries a Buy Rating with an average price forecast of $13.67, with recent analyst actions indicating a positive outlook [8]. - D. Boral Capital has a Buy rating with a target of $24.00, while Jefferies has raised its target to $9.00 [9]. Market Position - ImmunityBio's Benzinga Edge scorecard indicates strong momentum, with a bullish score of 70.55/100, suggesting the stock is outperforming the broader market [10]. Recent Price Action - ImmunityBio shares were up 26.16% at $3.81 at the time of publication [11].

Financial Results Announcement - ImmunityBio, Inc. announced preliminary, unaudited financial results for the fiscal quarter and full year ending December 31, 2025[4] - The reported financial results are based on preliminary estimates and may differ materially from actual results to be disclosed in the Annual Report on Form 10-K[4] - The financial results are subject to the Company's financial closing procedures and final adjustments[4] - The Company has not yet finalized its operating results and financial position for the fiscal year ended December 31, 2025[4] Press Release Information - The press release regarding these results was issued on January 15, 2026[4] - The information provided in the press release is not deemed "filed" under the Securities Exchange Act of 1934[5] - The press release is included as Exhibit 99.1 in the Current Report on Form 8-K[6] Company Information - The Company is listed on The Nasdaq Global Select Market under the symbol IBRX[2] - The Company is incorporated in Delaware and has its principal executive offices in San Diego, California[1] - David C. Sachs serves as the Chief Financial Officer of ImmunityBio, Inc.[9]